文献速递肝病

长期持续特利加压素输注改善失代偿期肝硬化患者的心脏储备功能

Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-30

22例失代偿期肝硬化伴腹水患者接受居家持续特利加压素输注的前瞻性研究,在12周前后用多巴酚丁胺负荷超声心动图评估心脏功能。结果显示特利加压素后低剂量多巴酚丁胺引起的CO增加较基线显著升高,心脏储备受损比例从81.8%降至40.9%,静息CO和每搏量显著下降。

要点

  • 特利加压素后低剂量多巴酚丁胺引起的CO增加为↑4.0 L/min(↑57.8%),显著高于基线的↑1.8 L/min(21.3%)(P = .0001)。
  • 心脏储备受损(低剂量多巴酚丁胺后ΔCO <25%)比例从基线81.8%降至特利加压素后40.9%(P = .02)。
  • 静息CO从8.9 ± 2.2 L/min降至7.2 ± 1.8 L/min(P < .001),每搏量从108降至86 mL/beat(P = .006)。

核心结论

  • 长期持续特利加压素输注使心脏储备显著增加,并减轻失代偿期肝硬化常见的高动力状态。
  • 这些数据为肝硬化心脏功能障碍的发病机制和可逆性提供了重要机制性见解。
  • 未来研究需评估长期特利加压素能否在高危个体中预防肝肾综合征等肝脏失代偿事件。

研究设计与样本

  • 前瞻性研究,纳入22例失代偿期肝硬化伴腹水、参加居家持续特利加压素输注研究的患者。
  • 在特利加压素治疗前和12周后使用多巴酚丁胺负荷超声心动图评估心脏功能。
  • 主要结局为特利加压素对心脏储备(应激时心输出量变化)的影响。

主要发现

  • 中位年龄61岁(四分位距56-64岁),中位终末期肝病模型评分15(四分位距12.3-17.0),72.7%为男性。
  • 低剂量多巴酚丁胺引起的CO增加在特利加压素后为↑4.0 L/min(↑57.8%),显著高于基线的↑1.8 L/min(21.3%)(P = .0001)。
  • 心脏储备受损(低剂量多巴酚丁胺后ΔCO <25%)比例从基线81.8%降至特利加压素后40.9%(P = .02),主要由正性肌力功能改善驱动。
  • 静息CO从8.9 ± 2.2 L/min显著降至7.2 ± 1.8 L/min(正常范围5-6 L/min)(P < .001),每搏量从108降至86 mL/beat(P = .006)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 未来研究需评估长期特利加压素能否在高危个体中预防肝肾综合征等肝脏失代偿事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cardiac dysfunction is a key factor in the pathogenesis of hepatorenal syndrome, for which terlipressin is the recommended first-line treatment. This study investigates whether long-term terlipressin can ameliorate the subclinical cardiac dysfunction observed in decompensated cirrhosis. METHODS: Twenty-two patients with decompensated cirrhosis and ascites enrolled in a prospective study of home continuous terlipressin infusion were included. Cardiac function was assessed using dobutamine stress echocardiogram before and after 12 weeks of terlipressin. The primary outcome was the impact of terlipressin on cardiac reserve, the change in cardiac output (CO) in response to stress. RESULTS: The median age was 61 years (interquartile range, 56-64 years), the median Model for End-Stage Liver Disease score was 15 (interquartile range, 12.3-17.0), and 72.7% were male. The increase in CO in response to low-dose dobutamine was significantly higher following terlipressin (↑4.0 L/min [↑57.8%]) as compared with baseline (↑1.8 L/min [21.3%]) (P = .0001). The proportion of patients with impaired cardiac reserve (defined by ΔCO <25% after low-dose dobutamine) reduced from 81.8% at baseline to 40.9% after terlipressin, (P = .02), driven primarily by improvement in inotropic function. Resting CO decreased significantly after terlipressin from 8.9 ± 2.2 L/min to 7.2 ± 1.8 L/min (normal range 5-6 L/min) (P < .001), due to a decrease in stroke volume from 108 to 86 mL/beat (P = .006). CONCLUSIONS: Long-term continuous terlipressin infusion resulted in a significant increase in cardiac reserve and attenuation of the hyperdynamic state usually observed in decompensated cirrhosis. These data provide important mechanistic insight into the pathogenesis and reversibility of cardiac dysfunction in cirrhosis. Future studies are required to evaluate whether long-term terlipressin can prevent hepatic decompensating events such as hepatorenal syndrome in high-risk individuals. Australian New Zealand Clinical Trials Registry, Number: ACTRN12619000891123.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Terbah R, Koshy AN, Majumdar A, et al. Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2024. PMID: 39209185. doi:10.1016/j.cgh.2024.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。